摘要
孕酮受体配体(PRLs)通过孕酮受体介导发挥作用,有广泛的妇科疾病治疗前景。目前临床用药多为甾体类,不良反应多,临床应用极为有限。非甾体类PRLs具有高度的受体和组织选择性,有望降低不良反应,扩大其在临床上的应用。文中分类综述近年来非甾体类PRLs的研发进展,其中包括吲唑类、哒嗪类、苯并吡喃并喹啉类、苯并嗯嗪类、吲哚类、苯并咪唑和苯并噻唑类、氢化喹啉、吡唑类、二氮革类、苯并吲哚及萘并呋喃类化合物。
Progesterone receptor ligands (PRLs) function via progesterone receptor, and have potentially therapeutic applications in gynecological diseases. Because most clinically used drugs are steroidal derivatives and usually cause various adverse drug reactions, their applications are extremely limited. Nonsteroidal PRLs with high selectivity for receptors and tissues are expected to lower the adverse reactions, and to extend their uses in clinic. These PRLs developed in recent years are classified as indazoles, pyridazines, chrome-noquinolines, benzoxazines, indoles, benzimidazolones and benzothiazolones, quinolines, pyrazoles, diazepines, benzindolones, and naphtho- furanones.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2008年第11期905-910,共6页
Chinese Journal of New Drugs
关键词
非甾体类孕酮受体配体
子宫内膜异位症
子宫纤维瘤
构效关系
nonsteroidal progesterone receptor ligands
endometriosis
uterus fibroid
structure-activity relationship